2000 - Baxter spun off of its cardiovascular business as a separate, publicly traded entity under the name of Edwards Lifesciences.
Baxter joined four other leading healthcare companies to create the Global Healthcare Exchange, an independent, Internet-based company that facilitates the exchange of information related to buying, selling and distributing medical equipment, devices and healthcare products and related services worldwide.
Baxter´s North Cove, NC, facility received the Shingo Prize for Excellence in Manufacturing.
Baxter completed acquisition of Columbia, Maryland-based North American Vaccine.
2001 - Baxter´s Mountain Home, Arkansas, facility is named a recipient of the prestigious Shingo Prize for Excellence in Manufacturing.
Baxter acquired Cook Pharmaceutical Solutions, a manufacturer of prefilled injectable drugs in vials and syringes.
Baxter announced that it would participate in the production of approximately 155 million doses of smallpox vaccine for the U.S. government, in conjunction with Acambis Inc.
2002 - Baxter received clearance from the FDA to market the Accura Hemofiltration System for continuous renal replacement therapy (CRRT).
Baxter received FDA approval of EXTRANEAL PD solution, a non-glucose-based solution that provides increased fluid removal for some dialysis patients.
2003 - Baxter launched its ENLIGHTENEDHRBC bar code technology for flexible IV containers.
The FDA approved ADVATE, the first recombinant factor VIII concentrate for hemophilia made without any added human or animal proteins in the cell culture, purification and final formulation process, eliminating the risk of infections caused by viruses that may be carried in these proteins.
Baxter acquired certain assets from Alpha Therapeutic Corporation, including ARALAST, a plasma-based therapy to treat alpha-1 antitrypsin deficiency.
2004 - Baxter received regulatory approval to market ADVATE in Europe.
Baxter’s board of directors elected Robert L. Parkinson, Jr. as the company’s new chairman and chief executive officer.
Baxter and Halozyme Therapeutics entered into an exclusive sales and marketing agreement to commercialize HYLENEX, a recombinant form of human hyaluronidase that increases the spreading and absorption of other subcutaneously injected fluids and drugs.
2005 - Baxter received approval from the FDA for GAMMAGARD LIQUID for patients with immune-system disorders.
Baxter introduced FLEXBUMIN, the first albumin in a flexible, plastic container.
Baxter launched the inhalation anesthetic, Sevoflurane.
2006 - Baxter commemorated 75 years of leadership and innovation in healthcare. Click here to view the 75th Anniversary Video.
Baxter made Shanghai, China, the new location for its Asia Pacific regional headquarters.
The FDA approved ADEPT Adhesion Reduction Solution for use in gynecological laparoscopic procedures.
2007 - Baxter introduced the first needle-less IV connector with an antimicrobial coating.
2008 - Baxter received a positive opinion from regulatory authorities in Europe for CELVAPAN, the first cell culture-based H5N1 (avian flu) pandemic vaccine.
Baxter broke ground on a new R&D center in Belgium to replace the current R&D facility in Nivelles, where the company has operated since 1978.
Baxter received FDA approval of ARTISS fibrin sealant, the first commercially available slow-setting fibrin sealant used to adhere skin grafts in burn patients.
Baxter was named to the Dow Jones Sustainability Index (DJSI) for 10th consecutive year and the Medical Products Industry Leader for the seventh time since the DJSI was established in 1999.